会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Conformationally rigid bicyclic and adamantane derivatives useful as &agr;2-adrenergic blocking agents
    • 用作α2-肾上腺素能阻断剂的构象刚性双环和金刚烷衍生物
    • US06569884B2
    • 2003-05-27
    • US09846399
    • 2001-05-01
    • Stephen A. MunkJames A. BurkeMichael E. Garst
    • Stephen A. MunkJames A. BurkeMichael E. Garst
    • A61K31415
    • C07D413/12C07D233/50C07D263/28C07D277/18
    • A compound of formula I in which: ring A is one of the five alternative multi-cyclic rings as shown wherein a dotted line adjacent to a bond indicates that a single bond or a double bond may be present at that position; X is nitrogen, oxygen or sulfur; R is hydrogen, lower straight or branched chain alkyl of 1 to 6 carbon atoms, or lower straight or branched chain alkenyl of 2 to 6 carbon atoms, a cycloaliphatic ring of 3 to 6 carbon atoms, phenyl optionally mono- or di-substituted with hydroxy, halogen, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 2 carbon atoms, or methylenedioxyphenyl; or a stereoisomer, or a pharmaceutically acceptable salt thereof. These compounds have &agr;2 receptor blocking activity and hence find use in the treatment or palliation of elevated intraocular pressure, non insulin-dependent diabetes, male impotence and obesity.
    • 式Iin化合物,其中:环A是所示的五个替代多环之一,其中与键相邻的虚线表示在该位置可能存在单键或双键; X是氮,氧或硫; R为氢,1至6个碳原子的较低直链或支链烷基,或2至6个碳原子的较低直链或支链烯基,3至6个碳原子的脂环族环,任选被一个或二个取代 羟基,卤素,1至3个碳原子的烷基或1至2个碳原子的烷氧基,或亚甲二氧基苯基; 或其立体异构体或其药学上可接受的盐。这些化合物具有α2受体阻断活性,因此可用于治疗或缓解升高的眼内压,非胰岛素依赖性糖尿病,男性阳ence和肥胖。
    • 2. 发明授权
    • Conformationally rigid bicyclic and adamantane derivatives useful as &agr;2-adrenergic blocking agents
    • 用作α2-肾上腺素能阻断剂的构象刚性双环和金刚烷衍生物
    • US06319935B1
    • 2001-11-20
    • US09542216
    • 2000-04-04
    • Stephen A. MunkMichael E. GarstJames A. Burke
    • Stephen A. MunkMichael E. GarstJames A. Burke
    • A61K31425
    • C07D413/12C07D233/50C07D263/28C07D277/18
    • A compound of formula I in which: ring A is one of the five alternative multi-cyclic rings as shown wherein a dotted line adjacent to a bond indicates that a single bond or a double bond may be present at that position; X is nitrogen, oxygen or sulfur; R is hydrogen, lower straight or branched chain alkyl of 1 to 6 carbon atoms, or lower straight or branched chain alkenyl of 2 to 6 carbon atoms, a cycloaliphatic ring of 3 to 6 carbon atoms, phenyl optionally mono- or di-substituted with hydroxy, halogen, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 2 carbon atoms, or methylenedioxyphenyl; or a stereoisomer, or a pharmaceutically acceptable salt thereof. These compounds have &agr;2 receptor blocking activity and hence find use in the treatment or palliation of elevated intraocular pressure, non insulin-dependent diabetes, male impotence and obesity.
    • 式Iin化合物,其中:环A是所示的五个替代多环之一,其中与键相邻的虚线表示在该位置可能存在单键或双键; X是氮,氧或硫; R为氢,1至6个碳原子的较低直链或支链烷基,或2至6个碳原子的较低直链或支链烯基,3至6个碳原子的脂环族环,任选被一个或二个取代 羟基,卤素,1至3个碳原子的烷基或1至2个碳原子的烷氧基,或亚甲二氧基苯基; 或其立体异构体或其药学上可接受的盐。这些化合物具有α2受体阻断活性,因此可用于治疗或缓解升高的眼内压,非胰岛素依赖性糖尿病,男性阳ence和肥胖。
    • 4. 发明授权
    • Conformationally rigid bicyclic and adamantane derivatives useful as &agr;2-adrenergic blocking agents
    • 用作α2-肾上腺素能阻断剂的构象刚性双环和金刚烷衍生物
    • US06706747B2
    • 2004-03-16
    • US10393313
    • 2003-03-19
    • Stephen A. MunkJames A. BurkeMichael E. Garst
    • Stephen A. MunkJames A. BurkeMichael E. Garst
    • A61K31421
    • C07D413/12C07D233/50C07D263/28C07D277/18
    • A compound of formula I in which: ring A is one of the five alternative multi-cyclic rings as shown wherein a dotted line adjacent to a bond indicates that a single bond or a double bond may be present at that position; X is nitrogen, oxygen or sulfur; R is hydrogen, lower straight or branched chain alkyl of 1 to 6 carbon atoms, or lower straight or branched chain alkenyl of 2 to 6 carbon atoms, a cycloaliphatic ring of 3 to 6 carbon atoms, phenyl optionally mono- or di-substituted with hydroxy, halogen, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 2 carbon atoms, or methylenedioxyphenyl; or a stereoisomer, or a pharmaceutically acceptable salt thereof. These compounds have &agr;2 receptor blocking activity and hence find use in the treatment or palliation of elevated intraocular pressure, non insulin-dependent diabetes, male impotence and obesity.
    • 式Iin化合物,其中:环A是所示的五个替代多环之一,其中与键相邻的虚线表示在该位置可以存在单键或双键; X是氮,氧或硫; R为氢,1至6个碳原子的较低直链或支链烷基,或2至6个碳原子的较低直链或支链烯基,3至6个碳原子的脂环族环,任选被一个或二个取代 羟基,卤素,1至3个碳原子的烷基或1至2个碳原子的烷氧基,或亚甲二氧基苯基; 或其立体异构体或其药学上可接受的盐。这些化合物具有α2受体阻断活性,因此可用于治疗或缓解升高的眼内压,非胰岛素依赖性糖尿病,男性阳ence和肥胖。
    • 8. 发明授权
    • Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
    • 使用(2-咪唑啉-2-基氨基)喹喔啉衍生物的方法
    • US5418234A
    • 1995-05-23
    • US298494
    • 1994-08-30
    • Charles GluchowskiMichael E. GarstJames A. BurkeLarry A. WheelerMichael E. Garst
    • Charles GluchowskiMichael E. GarstJames A. BurkeLarry A. WheelerMichael E. Garst
    • A61K31/495C07D403/12A61K31/50
    • C07D403/12A61K31/495Y10S514/816Y10S514/854Y10S514/93
    • A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; the R.sub.2 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the R.sub.3 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the 2-imidazolin-2-ylamino group may be in any of the 5-, 6, 7- or 8-positions of the quinoxaline nucleus; and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals having 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as reduction in peripheral pain and reduction in or prevention of at least one effect of ischemia.
    • 治疗哺乳动物的方法包括向哺乳动物施用有效量以在哺乳动物中提供所需治疗效果,所述化合物选自下列化合物:具有下式的那些化合物:其药学上可接受的酸加成盐及其混合物, 其中R 1和R 4独立地选自H和具有1至4个碳原子的烷基; R 2独立地选自H或具有1至4个碳原子的烷基,或者一起是氧代; R 3独立地选自H或具有1至4个碳原子的烷基,或者一起是氧代; 2-咪唑啉-2-基氨基可以在喹喔啉核的5-,6-或7-位中的任一个中; 并且R5,R6和R7各自位于喹喔啉核的剩余的5-,6-,7-或8-位中的一个,并且独立地选自Cl,Br,H和具有1至 3个碳原子。 当向哺乳动物施用时,这些化合物提供期望的治疗效果,例如减少外周疼痛和减少或预防至少一种局部缺血的作用。
    • 10. 发明授权
    • Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
    • 使用(2-咪唑啉-2-基氨基)喹喔啉衍生物的方法
    • US06323204B1
    • 2001-11-27
    • US09222844
    • 1998-12-30
    • James A. BurkeMichael E. GarstLarry A. Wheeler
    • James A. BurkeMichael E. GarstLarry A. Wheeler
    • A61K31495
    • A61K31/495A61K31/498
    • A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R1 and R2 each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8-positions of the quinoxaline nucleus, and R3, R4 and R5 each is located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as reduction in peripheral pain.
    • 治疗哺乳动物的方法包括向哺乳动物施用有效量以在哺乳动物中提供所需治疗效果,所述化合物选自具有下式的那些化合物:及其药学上可接受的酸加成盐及其混合物,其中R 1 并且R 2各自选自含有1至4个碳原子的烷基和含有1至4个碳原子的烷氧基,2-咪唑啉-2-基氨基可以在5-,6-,7- - 或8-位的喹喔啉核,R3,R4和R5各自位于喹喔啉核的剩余的5-,6-,7-或8-位之一,并且独立地选自Cl ,Br,H和含有1至3个碳原子的烷基。 当向哺乳动物施用时,这些化合物提供期望的治疗效果,例如减少外周疼痛。